Burton Singerman
Psychiatry · Johnstown, PANPI 1003813452
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $120,361 of the $143,816 with a category attached, or 83.7%. 18 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 40.5% of the total. Reporting peaked in 2021 at $37,172 and has fallen 99.7% since, to $98 in 2025. Among psychiatry clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 429 payments — averaging $335.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$58K
- AbbVie$40K
- Teva Pharmaceuticals USA, Inc.$21K
- Axsome Therapeutics, Inc.$16K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$7K
- Lundbeck LLC$556
- plus $2K from 12 others
Across 2 payments — averaging $1223.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$2K
What the payments were for
- Consulting fees$13,71310%
- Speaking & faculty fees$120,36184%
- Travel & lodging$2,5742%
- Food & beverage$6,8365%
- Education$3330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 97 | $58,239 |
| AbbVie(2 entities) | 112 | $39,967 |
| Teva Pharmaceuticals USA, Inc. | 41 | $21,134 |
| Axsome Therapeutics, Inc. | 16 | $15,571 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $6,508 |
| Lundbeck LLC | 40 | $556 |
| Alkermes, Inc. | 20 | $486 |
| Johnson & Johnson | 19 | $293 |
| Vanda Pharmaceuticals Inc. | 14 | $282 |
| Neurocrine Biosciences, Inc. | 13 | $242 |
| Sunovion Pharmaceuticals Inc. | 21 | $184 |
| Corium, LLC | 7 | $126 |
| Ironshore Pharmaceuticals Inc. | 5 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $54 |
| Almatica Pharma LLC | 2 | $37 |
| Sage Therapeutics, LLC | 1 | $19 |
| Neos Therapeutics, LP | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$143,816 in reported general payments places this provider in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trazodone Hcl | 19 | $244 |
| Oxcarbazepine | 11 | $242 |
| Clonazepam | 28 | $193 |
| Gabapentin | 12 | $132 |
| Lorazepam | 17 | $92 |
| Sertraline Hcl | 21 | $86 |
| Buspirone Hcl | 20 | $46 |
| Olanzapine | 13 | $39 |
| Risperidone | 12 | $16 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Almatica Pharma LLCSertraline Hcl | $37 | $8621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,838 psychiatry providers in Pennsylvania.
Other psychiatry in Johnstown
- Rebecca RomaPittsburgh$3.3M
- Robert NelsonWyomissing$2.2M
- Matthew BergerMoosic$1.7M
- Mark MattaNew Castle$847K
- Mayer AyyashPittsburgh$714K
- Daniel WeintraubPhiladelphia$647K
- Sachin MehtaBlue Bell$646K
- Jane JesseKingston$617K
- Michael ThasePhiladelphia$396K
- Michael KwiatBeaver$390K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.